Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
Thirty healthy women, aged 18 to 37, were randomly allocated to treatment with a desogestrel-containing oral contraceptive, with 20 women using a nine-week on, one-week off regimen, and 10 women using the traditional regimen. At 0, 3 and 12 months, blood samples were drawn for liver proteins, lipoproteins and hemostatic variables. No significant changes were observed between the two regimens. Sex hormone binding globulin (SHBG) and corticosteroid binding globulin (CBG, transcortin) were increased two- to four-fold, as a measure of estrogenicity. Minimal changes occurred within the lipoprotein cholesterol fractions, whereas there were some increases within the lipoprotein triglyceride fractions. Among the hemostatic variables, there were significant increases of fibrinogen, factor VII and thrombin/antithrombin III (TAT) complex. The coagulation inhibitors, antithrombin III, protein C and protein S, were essentially unchanged. A decrease of both tissue plasminogen activator antigen (t-PA) and tissue plasminogen activator inhibitor activity (PAI activity) of the fibrinolytic system was observed. A nine-week regimen does not seem to alter lipid metabolism and coagulation more than a three-week regimen.
Department of Obstetrics and Gynecology, Falu Hospital, Falun, Sweden.
A C
AC
Cachrimanidou
D
D
Hellberg
S
S
Nilsson
B
B
von Schoulz
N
N
Crona
A
A
Siegbahn
D000293:Adolescent; D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage* / Q000494:pharmacology; D017135:Desogestrel / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005167:Factor VII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000032:analysis; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000032:analysis / Q000037:antagonists & inhibitors; D014156:Transcortin / Q000032:analysis; D014280:Triglycerides / Q000097:blood
D003280:Contraceptives, Oral, Synthetic; D008074:Lipoproteins; D011486:Protein C; D017293:Protein S; D012738:Sex Hormone-Binding Globulin; D014280:Triglycerides; C046193:antithrombin III-protease complex; D017135:Desogestrel; D000990:Antithrombin III; D005167:Factor VII; D005340:Fibrinogen; D014156:Transcortin; D002784:Cholesterol; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator